Stock listing

Bridgebio Pharma, Inc.

Selected listing: A2PLX7 · LSX · EUR · DE

Bridgebio Pharma, Inc. (LS Exchange: A2PLX7), Health Technology. Latest release Oct 6, 2026: BridgeBio to Present New Acoramidis Data, Including Independent…

A2PLX7:LSXEURDEUpdated October 2, 2026

Ticker: LS Exchange: A2PLX7
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: LS Exchange
Currency: EUR

Latest news from Bridgebio Pharma, Inc.

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

October 6, 2026

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

October 6, 2026

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

October 6, 2026

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

October 5, 2026

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

October 4, 2026

All Bridgebio Pharma, Inc. news →

Events

Replays

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call
Mon, Aug 10, 2026 · 04:30 PM ET
Watch
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call
Thu, May 07, 2026 · 04:30 PM ET
Watch
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 04:30 PM ET
Watch

Research Bridgebio Pharma, Inc.

Bridgebio Pharma, Inc. company profile

View the public company page for Bridgebio Pharma, Inc. on 6ix.

Bridgebio Pharma, Inc. news

Read company news and market updates connected to Bridgebio Pharma, Inc..

Bridgebio Pharma, Inc. investor events

Find investor webinars, events, and replay context for Bridgebio Pharma, Inc..